サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1532064

網膜色素変性症の世界市場レポート 2024年

Retinitis Pigmentosa Global Market Report 2024

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
網膜色素変性症の世界市場レポート 2024年
出版日: 2024年08月12日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

網膜色素変性症市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は7.7％で、152億3,000万米ドルに成長します。予測期間に予想される成長は、網膜再生のための幹細胞研究の進展、個別化医療へのアプローチ、希少疾病用医薬品開発への投資の増加、遠隔医療サービスの拡大などに関連しています。予測期間中に予想される主な動向には、併用療法へのシフト、患者中心の臨床試験デザインの増加、価値に基づく価格設定モデルの採用、デジタル治療薬の統合などがあります。

ヘルスケア支出の増加は、今後数年間の網膜色素変性症市場の成長を促進すると予測されます。ヘルスケア支出には、特定の期間における治療、投薬、入院、予防医療などのヘルスケア商品およびサービスに対する総支出が含まれます。この支出は、ある人口におけるヘルスケア提供の全体的なコストを反映しています。ヘルスケア支出の増加は、先進医療技術のコスト上昇、高齢化、慢性疾患の蔓延に起因しています。網膜色素変性症では、ヘルスケア支出は診断方法の改善、効果的な治療法の開発、視力低下を管理するための支持的ケアの提供に向けられています。例えば、米国国立衛生研究所によると、米国の医療費は2022年に4.1％増の4兆5,000億米ドルに達し、2021年の3.2％増に比べ成長率が加速しています。このように、ヘルスケア支出の伸びが網膜色素変性症市場の拡大に拍車をかけています。

網膜色素変性症市場の大手企業は、この衰弱状態を管理し、治癒させる可能性のある、より効果的で的を絞ったソリューションを提供するため、遺伝子治療などの革新的な治療法の開発にますます力を注いでいます。網膜色素変性症（RP）の遺伝子治療は、機能的な遺伝子を送り込み、病気の原因となる欠陥遺伝子を置き換えたり、修復したりするものです。この最先端の治療は、網膜の光受容細胞に正常な機能を回復させることで、視力低下の進行を遅らせたり、食い止めたりすることを目的としています。例えば、ドイツに本社を置くバイオテクノロジー企業であるViGeneron GmbHは、2024年4月、CNGA1遺伝子の変異によって引き起こされるRPを治療するためにデザインされた遺伝子治療薬VG901の安全性、忍容性、有効性を評価するための第Ib相臨床試験を開始しました。本試験は、二遺伝子CNGA1変異による常染色体劣性RP患者を対象に、VG901の硝子体内注射を検討する非盲検、単群、用量漸増試験です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の網膜色素変性症市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の網膜色素変性症市場の実績：規模と成長, 2018-2023
  • 世界の網膜色素変性症市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界の網膜色素変性症市場：タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 常染色体劣性
  • 常染色体優性
  • X連鎖性
  • 世界の網膜色素変性症市場：治療別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • ビタミンA
  • ドコサヘキサエン酸（DHA）
  • カルシウムチャネル遮断薬
  • 遺伝子治療
  • 網膜義眼
  • その他の治療法
  • 世界の網膜色素変性症市場：診断方法別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 網膜電図
  • 視野検査
  • 遺伝子検査
  • その他の診断方法
  • 世界の網膜色素変性症市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他の流通チャネル
  • 世界の網膜色素変性症市場：エンドユーザー別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院
  • 専門クリニック
  • ホームケア
  • その他のエンドユーザー

第7章 地域別・国別分析

  • 世界の網膜色素変性症市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界の網膜色素変性症市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 網膜色素変性症市場：競合情勢
  • 網膜色素変性症市場：企業プロファイル
    • Johnson & Johnson
    • Novartis AG
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.

第31章 その他の大手企業と革新的企業

  • Sun Pharmaceutical Industries Ltd
  • Spark Therapeutics
  • REGENXBIO Inc.
  • Editas Medicine
  • IVERIC bio
  • MeiraGTx Holdings
  • Gensight Biologics
  • Second Sight Medical Products
  • Copernicus Therapeutics Inc.
  • Kiora Pharmaceuticals
  • 4D Molecular Therapeutics
  • ReNeuron Group
  • Acucela Inc.
  • AGTC（Applied Genetic Technologies Corporation）
  • Editgene

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r18971

Retinitis pigmentosa (RP) is a group of inherited disorders that cause progressive degeneration of the retina, leading to vision loss. It primarily affects photoreceptor cells (rods and cones), resulting in symptoms such as night blindness and tunnel vision. Over time, RP can lead to significant visual impairment and blindness.

The main types of retinitis pigmentosa include autosomal recessive, autosomal dominant, and X-linked. Autosomal recessive retinitis pigmentosa (AR-RP) is a form of the disease where a person must inherit two copies of the mutated gene, one from each parent, to be affected. Treatment options for retinitis pigmentosa include vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, and retinal eye prosthetics, among others. The condition is diagnosed using methods such as electroretinogram, visual field testing, and genetic testing. Distribution channels for treatments include hospital pharmacies, retail pharmacies, and online pharmacies, and these treatments are utilized by various end-users such as hospitals, specialty clinics, and home care providers.

The retinitis pigmentosa market research report is one of a series of new reports from The Business Research Company that provides retinitis pigmentosa market statistics, including retinitis pigmentosa industry global market size, regional shares, competitors with a retinitis pigmentosa market share, detailed retinitis pigmentosa market segments, market trends and opportunities, and any further data you may need to thrive in the retinitis pigmentosa industry. This retinitis pigmentosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinitis pigmentosa market size has grown strongly in recent years. It will grow from $10.52 billion in 2023 to $11.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to advancements in genetic research, the development of retinal imaging technologies, increased awareness campaigns, the rise of patient advocacy groups, and the expansion of clinical trial networks.

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth expected in the forecast period can be linked to advancements in stem cell research for retinal regeneration, personalized medicine approaches, increased investment in orphan drug development, and the expansion of telemedicine services. Major trends anticipated in the forecast period include a shift towards combination therapies, an increase in patient-centric clinical trial designs, the adoption of value-based pricing models, and the integration of digital therapeutics.

The rise in healthcare expenditure is anticipated to drive the growth of the retinitis pigmentosa market in the coming years. Healthcare expenditure encompasses the total spending on healthcare goods and services, including medical treatments, medications, hospitalizations, and preventive care, over a specific period. This expenditure reflects the overall cost of providing healthcare within a population. The increase in healthcare expenditure is attributed to the rising costs of advanced medical technologies, an aging population, and the prevalence of chronic diseases. For retinitis pigmentosa, healthcare spending is directed towards improving diagnostic methods, developing effective treatments, and offering supportive care to manage vision loss. For example, according to the National Institutes of Health, healthcare expenditure in the US grew by 4.1% in 2022, reaching $4.5 trillion, a faster growth rate compared to the 3.2% increase in 2021. Thus, the growth in healthcare expenditure is fueling the expansion of the retinitis pigmentosa market.

Leading companies in the retinitis pigmentosa market are increasingly focusing on developing innovative treatments, such as gene therapy, to provide more effective and targeted solutions for managing and potentially curing this debilitating condition. Gene therapy for retinitis pigmentosa (RP) involves delivering functional genes to replace or repair the defective ones causing the disease. This cutting-edge treatment aims to restore normal function to the affected photoreceptor cells in the retina, thereby slowing or potentially halting the progression of vision loss. For instance, in April 2024, ViGeneron GmbH, a biotechnology company based in Germany, initiated a Phase Ib clinical trial to evaluate the safety, tolerability, and efficacy of VG901, a gene therapy designed to treat RP caused by mutations in the CNGA1 gene. This trial is an open-label, single-arm, dose-escalation study investigating the intravitreal injection of VG901 in patients with autosomal recessive RP due to biallelic CNGA1 mutations.

In December 2023, Thea Pharma Inc., a pharmaceutical company based in France, acquired two antisense oligonucleotide (AON) treatments, Sepofarsen (LCA10) and Ultevursen (USH2A), from ProQR Therapeutics NV for an undisclosed amount. This acquisition aligns with Thea's focus on rare genetic eye diseases and ophthalmology. ProQR Therapeutics NV, a biotechnology company based in the Netherlands, specializes in developing treatments for retinitis pigmentosa.

Major companies operating in the retinitis pigmentosa market are Johnson & Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, ReNeuron Group, Acucela Inc., AGTC (Applied Genetic Technologies Corporation), Editgene

North America was the largest region in the retinitis pigmentosa market in 2023. The regions covered in the retinitis pigmentosa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinitis pigmentosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinitis pigmentosa market consists of revenues earned by entities by providing services such as genetic counseling, low vision therapy, psychological support, and educational support. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinitis pigmentosa market also includes sales of retinal implants, screen readers, telescopic glasses, and adaptive lighting. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinitis Pigmentosa Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinitis pigmentosa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinitis pigmentosa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinitis pigmentosa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Autosomal Recessive; Autosomal Dominant; X-Linked
  • 2) By Treatment: Vitamin A; Docosahexaenoic Acid (DHA); Calcium Channel Blockers; Gene Therapy; Retinal Eye Prosthetics; Other Treatments
  • 3) By Diagnosis: Electroretinogram; Visual Field Testing; Genetic Testing; Other Diagnosis
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
  • 5) By End-users: Hospitals; Specialty Clinics; Homecare; Other End-users
  • Companies Mentioned: Johnson & Johnson; Novartis AG; AbbVie Inc.; Astellas Pharma Inc.; Biogen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinitis Pigmentosa Market Characteristics

3. Retinitis Pigmentosa Market Trends And Strategies

4. Retinitis Pigmentosa Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Retinitis Pigmentosa Market Size and Growth

  • 5.1. Global Retinitis Pigmentosa Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Retinitis Pigmentosa Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Retinitis Pigmentosa Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Retinitis Pigmentosa Market Segmentation

  • 6.1. Global Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Autosomal Recessive
  • Autosomal Dominant
  • X-Linked
  • 6.2. Global Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vitamin A
  • Docosahexaenoic Acid (DHA)
  • Calcium Channel Blockers
  • Gene Therapy
  • Retinal Eye Prosthetics
  • Other Treatments
  • 6.3. Global Retinitis Pigmentosa Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Electroretinogram
  • Visual Field Testing
  • Genetic Testing
  • Other Diagnosis
  • 6.4. Global Retinitis Pigmentosa Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Other Distribution Channels
  • 6.5. Global Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-users

7. Retinitis Pigmentosa Market Regional And Country Analysis

  • 7.1. Global Retinitis Pigmentosa Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Retinitis Pigmentosa Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Retinitis Pigmentosa Market

  • 8.1. Asia-Pacific Retinitis Pigmentosa Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Retinitis Pigmentosa Market

  • 9.1. China Retinitis Pigmentosa Market Overview
  • 9.2. China Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Retinitis Pigmentosa Market

  • 10.1. India Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Retinitis Pigmentosa Market

  • 11.1. Japan Retinitis Pigmentosa Market Overview
  • 11.2. Japan Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Retinitis Pigmentosa Market

  • 12.1. Australia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Retinitis Pigmentosa Market

  • 13.1. Indonesia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Retinitis Pigmentosa Market

  • 14.1. South Korea Retinitis Pigmentosa Market Overview
  • 14.2. South Korea Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Retinitis Pigmentosa Market

  • 15.1. Western Europe Retinitis Pigmentosa Market Overview
  • 15.2. Western Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Retinitis Pigmentosa Market

  • 16.1. UK Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Retinitis Pigmentosa Market

  • 17.1. Germany Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Retinitis Pigmentosa Market

  • 18.1. France Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Retinitis Pigmentosa Market

  • 19.1. Italy Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Retinitis Pigmentosa Market

  • 20.1. Spain Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Retinitis Pigmentosa Market

  • 21.1. Eastern Europe Retinitis Pigmentosa Market Overview
  • 21.2. Eastern Europe Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Retinitis Pigmentosa Market

  • 22.1. Russia Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Retinitis Pigmentosa Market

  • 23.1. North America Retinitis Pigmentosa Market Overview
  • 23.2. North America Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Retinitis Pigmentosa Market

  • 24.1. USA Retinitis Pigmentosa Market Overview
  • 24.2. USA Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Retinitis Pigmentosa Market

  • 25.1. Canada Retinitis Pigmentosa Market Overview
  • 25.2. Canada Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Retinitis Pigmentosa Market

  • 26.1. South America Retinitis Pigmentosa Market Overview
  • 26.2. South America Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Retinitis Pigmentosa Market

  • 27.1. Brazil Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Retinitis Pigmentosa Market

  • 28.1. Middle East Retinitis Pigmentosa Market Overview
  • 28.2. Middle East Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Retinitis Pigmentosa Market

  • 29.1. Africa Retinitis Pigmentosa Market Overview
  • 29.2. Africa Retinitis Pigmentosa Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Retinitis Pigmentosa Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Retinitis Pigmentosa Market, Segmentation By End-users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Retinitis Pigmentosa Market Competitive Landscape And Company Profiles

  • 30.1. Retinitis Pigmentosa Market Competitive Landscape
  • 30.2. Retinitis Pigmentosa Market Company Profiles
    • 30.2.1. Johnson & Johnson
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Astellas Pharma Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Biogen Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Retinitis Pigmentosa Market Other Major And Innovative Companies

  • 31.1. Sun Pharmaceutical Industries Ltd
  • 31.2. Spark Therapeutics
  • 31.3. REGENXBIO Inc.
  • 31.4. Editas Medicine
  • 31.5. IVERIC bio
  • 31.6. MeiraGTx Holdings
  • 31.7. Gensight Biologics
  • 31.8. Second Sight Medical Products
  • 31.9. Copernicus Therapeutics Inc.
  • 31.10. Kiora Pharmaceuticals
  • 31.11. 4D Molecular Therapeutics
  • 31.12. ReNeuron Group
  • 31.13. Acucela Inc.
  • 31.14. AGTC (Applied Genetic Technologies Corporation)
  • 31.15. Editgene

32. Global Retinitis Pigmentosa Market Competitive Benchmarking

33. Global Retinitis Pigmentosa Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Retinitis Pigmentosa Market

35. Retinitis Pigmentosa Market Future Outlook and Potential Analysis

  • 35.1 Retinitis Pigmentosa Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Retinitis Pigmentosa Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Retinitis Pigmentosa Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer